Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CDK5RAP3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CDK5RAP3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CDK5RAP3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CDK5RAP3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CDK5RAP3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CDK5RAP3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CDK5RAP3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CDK5RAP3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003462020 | Esophagus | HGIN | cellular response to unfolded protein | 36/2587 | 96/18723 | 5.82e-09 | 3.88e-07 | 36 |
GO:007233127 | Esophagus | HGIN | signal transduction by p53 class mediator | 49/2587 | 163/18723 | 5.71e-08 | 3.06e-06 | 49 |
GO:002241120 | Esophagus | HGIN | cellular component disassembly | 102/2587 | 443/18723 | 8.31e-08 | 4.33e-06 | 102 |
GO:190018216 | Esophagus | HGIN | positive regulation of protein localization to nucleus | 30/2587 | 87/18723 | 8.74e-07 | 3.59e-05 | 30 |
GO:004217720 | Esophagus | HGIN | negative regulation of protein catabolic process | 37/2587 | 121/18723 | 1.47e-06 | 5.56e-05 | 37 |
GO:190018017 | Esophagus | HGIN | regulation of protein localization to nucleus | 40/2587 | 136/18723 | 1.69e-06 | 6.31e-05 | 40 |
GO:000734610 | Esophagus | HGIN | regulation of mitotic cell cycle | 98/2587 | 457/18723 | 4.39e-06 | 1.42e-04 | 98 |
GO:190179827 | Esophagus | HGIN | positive regulation of signal transduction by p53 class mediator | 13/2587 | 25/18723 | 6.62e-06 | 2.07e-04 | 13 |
GO:003009927 | Esophagus | HGIN | myeloid cell differentiation | 83/2587 | 381/18723 | 1.26e-05 | 3.52e-04 | 83 |
GO:00447729 | Esophagus | HGIN | mitotic cell cycle phase transition | 89/2587 | 424/18723 | 2.80e-05 | 7.21e-04 | 89 |
GO:003096817 | Esophagus | HGIN | endoplasmic reticulum unfolded protein response | 24/2587 | 74/18723 | 3.39e-05 | 8.61e-04 | 24 |
GO:19019906 | Esophagus | HGIN | regulation of mitotic cell cycle phase transition | 65/2587 | 299/18723 | 1.12e-04 | 2.36e-03 | 65 |
GO:003410127 | Esophagus | HGIN | erythrocyte homeostasis | 34/2587 | 129/18723 | 1.16e-04 | 2.43e-03 | 34 |
GO:004593626 | Esophagus | HGIN | negative regulation of phosphate metabolic process | 89/2587 | 441/18723 | 1.24e-04 | 2.54e-03 | 89 |
GO:004873225 | Esophagus | HGIN | gland development | 88/2587 | 436/18723 | 1.34e-04 | 2.71e-03 | 88 |
GO:001056326 | Esophagus | HGIN | negative regulation of phosphorus metabolic process | 89/2587 | 442/18723 | 1.34e-04 | 2.71e-03 | 89 |
GO:19033228 | Esophagus | HGIN | positive regulation of protein modification by small protein conjugation or removal | 35/2587 | 138/18723 | 2.11e-04 | 3.88e-03 | 35 |
GO:006100820 | Esophagus | HGIN | hepaticobiliary system development | 37/2587 | 150/18723 | 2.58e-04 | 4.53e-03 | 37 |
GO:190179627 | Esophagus | HGIN | regulation of signal transduction by p53 class mediator | 26/2587 | 93/18723 | 2.60e-04 | 4.55e-03 | 26 |
GO:004232620 | Esophagus | HGIN | negative regulation of phosphorylation | 78/2587 | 385/18723 | 2.77e-04 | 4.77e-03 | 78 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDK5RAP3 | SNV | Missense_Mutation | novel | c.814N>T | p.Pro272Ser | p.P272S | Q96JB5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
CDK5RAP3 | SNV | Missense_Mutation | novel | c.1164C>A | p.Phe388Leu | p.F388L | Q96JB5 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
CDK5RAP3 | SNV | Missense_Mutation | novel | c.371N>G | p.Glu124Gly | p.E124G | Q96JB5 | protein_coding | deleterious(0) | possibly_damaging(0.894) | TCGA-C8-A273-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CDK5RAP3 | SNV | Missense_Mutation | novel | c.371N>G | p.Glu124Gly | p.E124G | Q96JB5 | protein_coding | deleterious(0) | possibly_damaging(0.894) | TCGA-E9-A1NF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
CDK5RAP3 | insertion | Frame_Shift_Ins | novel | c.354_355insGGCCC | p.Met119GlyfsTer3 | p.M119Gfs*3 | Q96JB5 | protein_coding | | | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
CDK5RAP3 | insertion | Nonsense_Mutation | novel | c.355_356insGACTTTGAGAGGTCAGTCCCAT | p.Met119ArgfsTer3 | p.M119Rfs*3 | Q96JB5 | protein_coding | | | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
CDK5RAP3 | deletion | Frame_Shift_Del | novel | c.528delN | p.Ala177GlnfsTer32 | p.A177Qfs*32 | Q96JB5 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CDK5RAP3 | SNV | Missense_Mutation | | c.832C>T | p.Pro278Ser | p.P278S | Q96JB5 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-C5-A7CO-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
CDK5RAP3 | SNV | Missense_Mutation | | c.530N>A | p.Ala177Glu | p.A177E | Q96JB5 | protein_coding | tolerated(0.94) | benign(0.148) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
CDK5RAP3 | SNV | Missense_Mutation | | c.450G>T | p.Glu150Asp | p.E150D | Q96JB5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |